MBX Biosciences, Inc.
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 62.51% | 80.42% | 82.08% | 45.58% | 53.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.00% | 30.90% | 99.26% | 86.27% | 79.19% |
| Operating Income | -22.00% | -30.90% | -99.26% | -86.27% | -79.19% |
| Income Before Tax | -19.16% | -22.41% | -93.56% | -76.25% | -78.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.16% | -22.41% | -93.56% | -76.25% | -78.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.16% | -22.41% | -93.56% | -76.25% | -78.53% |
| EBIT | -22.00% | -30.90% | -99.26% | -86.27% | -79.19% |
| EBITDA | -22.21% | -31.03% | -99.40% | -86.45% | -79.16% |
| EPS Basic | 77.30% | 95.40% | 93.03% | 93.96% | 70.37% |
| Normalized Basic EPS | 77.30% | 95.40% | 93.03% | 93.58% | 70.37% |
| EPS Diluted | 77.30% | 95.40% | 93.03% | 93.96% | 70.37% |
| Normalized Diluted EPS | 77.30% | 95.40% | 93.03% | 93.58% | 70.37% |
| Average Basic Shares Outstanding | 424.87% | 2,561.87% | 2,678.81% | 2,817.40% | 502.57% |
| Average Diluted Shares Outstanding | 424.87% | 2,561.87% | 2,678.81% | 2,817.40% | 502.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |